Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.

Diabetes Obes Metab · 2018 · PMC5887932 · PMID 29171700

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

difference was apparentno p-value reported

95 In the same population, no interclass difference was apparent for DPP4i with regard to the risk of hospitalization for HF. 107 These results, along with the overall tolerability profile, make DPP4i an attractive and safe treatment in the early stage of the disease.

also in 830 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.